Patent incoming29 Aug 2025 09:59
Professor Nutt head of newly Scientific advisor Committee.
A new age of CNS drug discovery is upon us and it's patent protected and has an SAC set up with Nutt at the helm.
Solvonis and Nutt have a library Being assisted by AI.
They could well become a library of knowledge for numerous drug developers.
Allowance of U.S. patent covering AI-supported CNS discovery programme compounds
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that the U.S. Patent and Trademark Office (the "USPTO") has allowed a key patent application protecting compounds within the Company's AI-enabled CNS discovery programme.
The application-U.S. No. 18/838,986, titled "Bridged Ring Compounds and Their Therapeutic Use as CNS Agents"-received a first-action allowance with no objections or rejections. The claims cover composition of matter and methods of use for a family of novel morpholine-class compounds, originally developed by Awakn Life Sciences Corp. and now central to Solvonis' Central Nervous System ("CNS") library.
An "allowance" confirms that a patent will be granted, subject only to final administrative steps.
The CNS library, which includes multiple chemically distinct, preclinically validated series, underpins Solvonis' AI-supported drug discovery platform. The patent adds meaningful protection across novel CNS chemical space, especially in depression, stimulant use disorder and other neuropsychiatric conditions.
The patent, expected to be granted in the coming months, will confer U.S. exclusivity through to at least 2043, reinforcing the long-term value of Solvonis' early-stage pipeline.
Sign In
Follow the stocks
